Addiction Medicine Physician Salary Guide 2026: MOUD, OTP, and SUD Income Breakdown

Addiction medicine physician salary overview 2026

Addiction medicine is a multi-specialty subspecialty — physicians who practice addiction medicine come from internal medicine, family medicine, emergency medicine, psychiatry, and other backgrounds, completing a one-year addiction medicine fellowship and ABAM board certification. Mean total compensation in 2026 ranges from $190,000–$300,000 in academic settings, $200,000–$340,000 in employed health system inpatient consultation or outpatient SUD clinic positions, and $240,000–$450,000 in opioid treatment program (OTP) medical director or physician roles and high-volume private MOUD practices. The specialty is experiencing significant growth driven by the ongoing opioid epidemic, expanding Medicaid coverage for SUD treatment, and the 2023 SAMHSA rule eliminating the X-waiver requirement for buprenorphine prescribing — allowing any DEA-licensed physician to prescribe without prior certification.

Income by practice setting

• Academic addiction medicine: $190,000–$300,000; research on treatment outcomes, naloxone distribution, contingency management, and integrated care models; NIDA grant funding (R01, K awards); bridge program and hospital consult service; addiction psychiatry overlap common; lowest income but strongest research and teaching infrastructure
• Employed health system outpatient SUD clinic: $200,000–$320,000; office-based opioid treatment (OBOT) buprenorphine clinic; alcohol use disorder management (naltrexone, acamprosate, disulfiram); SBIRT programs; integrated with behavioral health and primary care; wRVU production bonus structure in most health systems
• Hospital-based SUD consultation service: $220,000–$340,000; inpatient consultation for substance use disorders; acute withdrawal management (CIWA-Ar for alcohol, COWS for opioids); MOUD initiation during hospitalization; bridge prescriptions at discharge; collaboration with social work and case management for warm handoffs to outpatient treatment
• Opioid treatment program (OTP) medical director: $250,000–$420,000; highly regulated methadone maintenance treatment programs; federal (SAMHSA) and state OTP certification; medical director responsible for patient evaluation, methadone dosing certification, urine drug screen oversight, and regulatory compliance; medical director administrative stipend $40,000–$100,000/year on top of clinical salary; OTPs can be non-profit, state-operated, or for-profit
• Private MOUD / telemedicine addiction medicine: $240,000–$450,000; telehealth buprenorphine prescribing (enabled by the COVID flexibilities made permanent by the 2023 SAMHSA rule); direct patient subscription or fee-for-service model; telehealth MOUD platforms (Bicycle Health, Ophelia, Groups, Done Health) employ physicians as contractors; high hourly rates ($150–$300/hour clinical time) with flexible scheduling

Billing codes and revenue drivers

• Office-based opioid treatment (OBOT) E&M: CPT 99213–99215 (established patient); $150–$350 per visit; monthly or more frequent visits for stable buprenorphine patients; high panel volume (100–300+ active MOUD patients) with monthly touchpoints generates strong recurring E&M revenue; telehealth billing at same rates as in-person for Medicare (through 2026 flexibilities)
• MOUD initiation visit: CPT 99205 (new patient, high complexity) + CPT 99408 (SBIRT alcohol/drug intervention, 15–30 min) + CPT 99409 (SBIRT, 30+ min); $300–$600 for initial comprehensive assessment; high complexity justified by multiple comorbidities, risk stratification, PDMP review, and treatment planning
• SBIRT (Screening, Brief Intervention, Referral to Treatment): CPT 99408 (15–30 min) / 99409 (30+ min); $50–$130; Medicaid and commercial billing for structured brief alcohol and drug intervention during primary care or specialty visits; SBIRT is Medicare-covered in some settings and Medicaid-covered in most states with SUD parity laws
• Naltrexone IM injection (Vivitrol): CPT 96372 (SC/IM injection administration); J-code J2315; $900–$1,500/injection drug cost; administration fee $50–$150; monthly injection for alcohol use disorder and opioid use disorder (following opioid-free period); buy-and-bill at physician office generates drug margin; manufacturer patient assistance programs reduce access barriers for uninsured patients
• Urine drug screen (UDS) — qualitative immunoassay: CPT 80305 (presumptive, point-of-care cup) / 80306 (reader device) / 80307 (instrument-based); $20–$150 depending on method; UDS monitoring is a regulatory requirement in OTPs and standard of care in OBOT; in-office point-of-care cup testing (80305) is the most common; confirmation GC-MS/LC-MS (CPT 80320–80377 per drug class) for disputed or positive results
• Quantitative drug testing (confirmatory): CPT 80320–80377 per drug or drug class; $30–$150 per class; sent to reference laboratory; required for methadone level confirmation and medico-legal documentation in OTP; generates significant laboratory billing in high-volume OTP settings
• Alcohol biomarkers: CPT 82055 (ethanol breath or urine), 82607 (B12 for alcohol-related deficiency screening), G0480 (EtG/EtS confirmatory testing); $50–$200; alcohol use monitoring in AUD patients on naltrexone or acamprosate
• Buprenorphine induction (hospital): E&M codes plus CPT 99213 equivalent; low-dose buprenorphine induction (microdosing Bernese method) for patients on full opioid agonists; increasingly performed in emergency department and inpatient settings; drives discharge prescription volume and warm handoff to outpatient MOUD
• Chronic care management (CCM, CPT 99490): $65–$120/month; non-face-to-face care coordination for SUD patients with co-occurring chronic conditions (hepatitis C, HIV, chronic pain, PTSD); delegatable to care coordinators under physician supervision; 200-patient CCM panel generates $156,000–$288,000/year in recurring monthly billing with minimal physician time
• Behavioral health integration (BHI, CPT 99484): $50–$100/month; primary care behavioral health integration for patients with SUD co-managed in primary care setting; growing CoCM (collaborative care model) integration driving addiction medicine physician consulting role

The X-waiver elimination and telehealth expansion

The two most significant regulatory changes in addiction medicine in the past five years are (1) the elimination of the DEA X-waiver requirement for buprenorphine prescribing (December 2022, operationalized 2023) and (2) the COVID-era telehealth flexibilities allowing buprenorphine initiation via telehealth without prior in-person evaluation (made permanent through 2026 at minimum by the SUPPORT Act and CURES 2.0). The X-waiver elimination expanded the eligible prescriber pool from 130,000 waivered providers to every DEA-registered physician in the country — estimated 1.1 million physicians. Telehealth MOUD allows patients in rural areas, individuals without transportation, and those with work or childcare barriers to access evidence-based treatment. Addiction medicine physicians who establish telehealth MOUD practices can serve patients across state lines (with appropriate multi-state licensure), significantly expanding their patient panel and revenue potential beyond geographic catchment area constraints.

Geographic variation in addiction medicine compensation

• Major metro health systems (NYC, Chicago, Boston, Philadelphia, LA): $220,000–$340,000 employed; high SUD burden; hospital SUD consultation services well-established; academic addiction medicine programs at medical schools; Medicaid expansion states with SUD parity (MA, CA, NY) have strongest insurance coverage for MOUD
• Appalachian and rural opioid-crisis markets (WV, KY, OH, TN, PA rural): $240,000–$380,000; highest per-capita OUD burden nationally; OTP density high; state and federal opioid crisis funding supplementing clinical revenue; NHSC and rural health center LRP available; significant shortage of addiction medicine trained physicians creating premium compensation environment
• Sun Belt markets (FL, TX, AZ, GA): $220,000–$360,000; growing Medicaid SUD benefit coverage in expansion states; private OTP and OBOT clinic culture active in FL; telehealth MOUD demand high in TX and AZ (rural access gaps)
• Rural and frontier markets: $230,000–$400,000; NHSC and rural health center funding available; telehealth MOUD serves geographic gap populations; highest loan repayment incentive availability; lowest overhead environment for solo OBOT practice

What we see at Ava Health

Addiction medicine is one of the fastest-growing physician subspecialties by demand, driven by the opioid epidemic, the X-waiver elimination, and Medicaid SUD parity implementation — and one of the most underrepresented in traditional healthcare recruiting pipelines. The physicians in our network who practice addiction medicine report the highest proportion of intrinsic career satisfaction of any specialty group: the work is longitudinal, the outcomes are measurable (patients remaining in treatment, negative UDS, employment, housing stability), and the patient relationships are often transformative. For hospitals and health systems recruiting addiction medicine physicians, the evidence that hospital-based SUD consultation services reduce readmissions, total cost of care, and avoidable ED visits is now sufficiently robust to justify the business case independently of value-based care incentives — and programs that lead with this evidence in their physician recruitment pitch attract stronger candidates than those who lead with salary alone.

Related: Psychiatrist Salary Guide, PMHNP Salary Guide, Internal Medicine Salary Guide, Family Medicine Salary Guide.